Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus
✍ Scribed by Paolo Bidoli; Emilio Bajetta; Simonetta C. Stani; Daniela De Candis; Armando Santoro; Maurizio Valente; Roberto Zucali; Pinuccia Valagussa; Gianni Ravasi; Gianni Bonadonna
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 92 KB
- Volume
- 94
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
BACKGROUND
The effects of multimodality treatment on the survival of patients with esophageal carcinoma are unclear. The authors performed a prospective, Phase II study to assess the long‐term results of chemotherapy plus radiotherapy (RT) on patients with esophageal squamous cell carcinoma.
METHODS
Of 106 consecutive patients who were recruited between 1985 and 1992, 101 patients were evaluable. Cisplatin (100 mg/m^2^ per day) on Day 1 and fluorouracil (1000 mg/m^2^ per day) on Days 1–4 were given for two cycles, with concomitant RT (30 grays [Gy] in 15 fractions) over 19 days. Patients with potentially resectable tumors were then assessed for curative surgery; the other patients received two more courses of chemotherapy and further RT (20 Gy in 10 fractions).
RESULTS
Of 40 patients who were candidates for surgery, 32 patients underwent surgery, and 24 patients had complete resection; 8 patients (25%) had no residual tumor in the specimen, and 12 patients (37%) had microscopic foci only. Surgical mortality was high (22%). Of 61 nonsurgical patients, 37 patients (61%) achieved complete clinical remission, and 14 patients (23%) achieved partial remission. The median survival for the entire series was 15 months (range, 1–136 months). The overall survival rate was 22% at 5 years and 12% at 10 years. At 10 years, freedom from disease progression was similar in the two groups (24%), whereas the median survival (22 months vs. 12 months) and the overall survival rates (17% vs. 9%) were better in nonsurgical patients compared with surgical patients, respectively, probably in relation to high surgical mortality. The larynx was preserved in 28% of 32 patients with cervical disease sites, with a 10‐year disease free survival rate of 31%. Three deaths were attributed to nonsurgical treatments.
CONCLUSIONS
Careful multidisciplinary pretreatment evaluation can identify patients who are ineligible for surgery without compromising long‐term results. For patients with inoperable disease, chemoradiotherapy can produce relatively good long‐term results. The combined approach without surgery can permit laryngeal preservation in a useful fraction of patients. Cancer 2002;94:352–61. © 2002 American Cancer Society.
📜 SIMILAR VOLUMES
## Abstract ## Background We have shown that rIL‐2 administration in recurrent head and neck cancers induces a tumor‐specific T‐lymphocyte reactivity and tumor regression; in a pilot study we have shown a safe and effective administration of rIL2 after cisplatin + 5‐fluorouracil. Long‐term results
## BACKGROUND. Surgery remains the treatment of choice for patients with esophageal squamous cell carcinoma (SCC), but survival rates have not improved over the past decades. The objective of this study was to evaluate the effect of multimodal therapy on resectability, on the overall and on diseas
Endoscopic laser therapy provides effective symptomatic palliation for patients with squamous cell carcinoma of the esophagus. To investigate whether this treatment also prolongs survival, a retrospective case-control study was performed. Ten patients with squamous cell carcinoma of the esophagus, d
## Abstract Based on our previous demonstration that elevated cyclooxygenase‐2 (COX‐2) expression is a prognostic factor for reduced survival in patients with adenocarcinoma of the esophagus, the aim of our study was to analyze the role of COX‐2 expression in esophageal squamous cell carcinoma. We
## Abstract ## BACKGROUND. Although adjuvant radiotherapy (RT) is often recommended for locally advanced squamous cell carcinoma of the head and neck (HNSCC), its effect on overall or cancer‐specific survival has not been clearly demonstrated. In the current study, the frequency and effect of adju